Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRI-RA: Baricitinib + anti-TNF vs baricitinib in rheumatoid arthritis
2024-511442-39-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of baricitinib, adalimumab and etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: ACR50 response at week 24. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-511442-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511442-39-00.